Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.

@article{Gasparri1999TumorPW,
  title={Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.},
  author={Anna Maria Gasparri and Monica Moro and Flavio Curnis and Ada Sacchi and Stefano Pagano and Fabrizio Veglia and Giulia Casorati and Antonio G Siccardi and Paolo Dellabona and Angelo Corti},
  journal={Cancer research},
  year={1999},
  volume={59 12},
  pages={2917-23}
}
The clinical use of tumor necrosis factor alpha (TNF) as an anticancer drug is limited to local or locoregional administration because of dose-limiting systemic toxicity. We investigated in animal models whether the therapeutic index of systemically administered human or murine TNF can be increased by tumor pretargeting strategies based on the biotin-avidin system. Pretargeting of s.c. mouse WEHI-164 fibrosarcoma and RMA lymphoma genetically engineered to express the Thy 1.1 antigen on the cell… CONTINUE READING